Skip to Content

Kovaltry Approval History

Kovaltry (antihemophilic factor (recombinant)) is a human DNA sequence derived, full length Factor VIII concentrate indicated for the control and prevention of bleeding episodes in adults and children with hemophilia A.

Hemophilia A is a largely inherited bleeding disorder characterized by missing or reduced factor VIII. It is treated by infusing replacement factor VIII intravenously. The approval of Kovaltry is based on results from the LEOPOLD (Long-Term Efficacy Open-Label Program in Severe Hemophilia A Disease) clinical trials, which supported the approval of Kovaltry for routine prophylaxis to reduce the frequency of bleeding episodes.

Kovaltry is administered via intravenous infusion up to two or three times per week. The most common side effects reported during clinical trials were headache, fever, and itchy rash.

Development History and FDA Approval Process for Kovaltry

Mar 17, 2016Approval FDA Approves Bayer's Kovaltry (Antihemophilic Factor (Recombinant)) for the Treatment of Children and Adults with Hemophilia A
Mar  4, 2015FDA Accepts Bayer's BLA for Investigational Treatment Option in Hemophilia A

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.